Compare Citius Pharmaceuticals Inc (CTXR) vs Waste Management, Inc. (WM) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

WM trades at $236.71, up 1.45% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages and a consensus analyst price target of $263.57. Recent earnings beat expectations in Q1 2026, with revenue growth to $25.20 billion in 2025. The company maintains solid profitability with a 10.99% net margin and offers a dividend, with the next payment scheduled for June 18, 2026.

Outlook remains positive due to pricing discipline and renewable energy initiatives, but high valuation multiples (P/E 34.26) and recent earnings misses pose risks. Institutional sentiment is bullish with no sell ratings, though debt levels have increased. Key near-term catalyst is Q2 2026 earnings release on July 28, 2026.